New £800-a-dose Covid drug that protects vulnerable patients - Daily Mail

Evusheld, developed by AstraZeneca, was approved by UK regulators in March - but the Department of Health and Social Care has refused to cover the £800-a-dose cost.

A drug proven to protect vulnerable patients still at risk from Covid can also radically slash their chances of dying if they do become infected, a study has discovered. Evusheld, developed by Astra… [+5928 chars]

full article...